Back

SGLT2 inhibitor outcomes in elderly post-MI patients with mildly reduced ejection fraction: age-stratified real-world evidence

29 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Acute heart failure therapies: timing, choices, and comparative effectiveness Pharmacotherapy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Ademola Ajibade

University of Iowa Hospitals and Clinics, Iowa City (United States of America)

5 More presentations in this session

Presentation thumbnail
Impact of levosimendan versus dobutamine on 30-day mortality and hospital stay in acute decompensated heart failure: a systematic review and meta-analysis
Doctor H. Amorim Parente (Rio de Janeiro, BR)
Abstract
Presentation thumbnail
From trials to treatment: real-world vericiguat initiation and residual risk in Germany
Doctor F. Kerwagen (Wuerzburg, DE)
Abstract
Presentation thumbnail
Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety
Doctor N. Benameur (Tangier, MA)
Abstract
Presentation thumbnail
Does initiating SGLT2 inhibitors at an early stage of heart failure admission really reduce cardiovascular mortality and first rehospitalization? A meta-analysis of randomized controlled trials
Doctor E. Alupei (RO)
Abstract
Presentation thumbnail
Early catheter ablation for atrial fibrillation in acute heart failure: prognostic impact across age and ejection fraction
Doctor A. Okahara (Fukuoka, JP)
Abstract

Access the full session

Session thumbnail
Acute heart failure therapies: timing, choices, and comparative effectiveness

The Event

Event poster

ESC Congress 2026

29 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Treatment with SGLT2 inhibitors in the early phase post acute myocardial infarction
15 March 2025
thumbnail
Congress Presentation
Is sacubitril/valsartan well tolerated in elderly heart failure patients with reduced ejection fraction? Preliminary data from a real-word registry.
29 June 2021
thumbnail
Congress Presentation
Prevention of new-onset heart failure and renoprotective effect with sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease
29 August 2025
thumbnail
Congress Presentation
Unlocking SGLT2 inhibitors: evaluating elderly HFrEF patients with and without T2DM
13 May 2024

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources